MRKR
Marker Therapeutics, Inc.Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.”View the 10-Q filed May 15, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2025-11-17 | Knobil Katharine |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for the remaining options due as service as a director for the year 2024. 30,000 shares were previously granted on February 12, 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025. |
Stock Option (Right to Buy)
|
84,411 |
| 2025-11-17 | Knobil Katharine |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for service as a director for the year 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025. |
Stock Option (Right to Buy)
|
137,330 |
| 2025-11-17 | Eansor Norman David |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for service as a director for the year 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025. |
Stock Option (Right to Buy)
|
137,330 |
| 2025-11-17 | ELMS STEVE |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for the remaining options due as service as a director for the year 2024. 30,000 shares were previously granted on February 12, 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025. |
Stock Option (right to buy)
|
84,411 |
| 2025-11-17 | Eansor Norman David |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for the remaining options due as service as a director for the year 2024. 30,000 shares were previously granted on February 12, 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025. |
Stock Option (Right to Buy)
|
84,411 |
| 2025-11-17 | ELMS STEVE |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for service as a director for the year 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025. |
Stock Option (right to buy)
|
137,330 |
| 2025-10-31 | Corzo Kathryn Penkus |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. The shares vest equally over thirty six (36) monthly installments, subject to the Reporting Person's continued service as a director. The option exercise price is the closing price on the date of the grant, October 31, 2025. |
Stock Option (Right to Buy)
|
147,611 |
| 2025-10-31 | Vera Juan |
Director |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One fourth of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second, third and fourth anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the closing price on the date of the grant, October 31, 2025. |
Employee Stock Option (right to buy)
|
250,000 |
| 2025-10-31 | Corzo Kathryn Penkus |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2025-02-12 | Vera Juan |
Director |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One third of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second and third anniversary of the grant date upon the continued performance of services by the Reporting Person to the Company through the vesting dates. The option exercise price is the closing price on the date of the grant, February 12, 2025. |
Employee Stock Option (right to buy)
|
50,000 |
| 2025-02-12 | ELMS STEVE |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One third of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second and third anniversary of the grant date subject to the Reporting Person's continued service as a director. The option exercise price is the closing price on the date of the grant, February 12, 2025. |
Stock Option (right to buy)
|
30,000 |
| 2025-02-12 | Eansor Norman David |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One third of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second and third anniversary of the grant date subject to the Reporting Person's continued service as a director. The option exercise price is the closing price on the date of the grant, February 12, 2025. |
Stock Option (right to buy)
|
30,000 |
| 2025-02-12 | Knobil Katharine |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One third of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second and third anniversary of the grant date subject to the Reporting Person's continued service as a director. The option exercise price is the closing price on the date of the grant, February 12, 2025. |
Stock Option (right to buy)
|
30,000 |
| 2024-12-23 | ELMS STEVE |
Director |
Buy↑
Filing footnotes — Common Stock (Indirect)
Acquired from the Issuer on December 23, 2024 pursuant to a Securities Purchase Agreement dated December 19, 2024. On January 26, 2023, the Issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. The reportable securities are directly owned by Aisling Capital IV, LP ("Aisling"), and which may be deemed to be beneficially owned by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms, who have shared voting and dispositive power over the shares. Mr. Elms, the Reporting Person, disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, and the inclusion of these securities herein shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purpose. |
Common Stock
(I)
|
11,085 |
| 2024-12-23 | New Enterprise Associates 16, L.P. |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Direct)
Acquired from the Issuer on December 23, 2024 pursuant to a Securities Purchase Agreement dated December 19, 2024. On January 26, 2023, the Issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. The securities are directly held by New Enterprise Associates 16, L.P. ("NEA 16"), and indirectly held by NEA Partners 16, L.P. ("NEA Partners 16"), the sole general partner of NEA 16, NEA 16 GP, LLC ("NEA 16 GP"), the sole general partner of NEA Partners 16, and the individual managers of NEA 16 GP (NEA Partners 16, NEA 16 GP and the individual managers of NEA 16 GP, together, the "Indirect Reporting Persons").The individual managers of NEA 16 GP are Forest Baskett, Ali Behbahani, Carmen Chang, Anthony A. Florence, Jr., Mohamad Makhzoumi, Scott D. Sandell, and Paul Walker. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares of the Issuer held by NEA 16 in which the Indirect Reporting Persons have no pecuniary interest. |
Common Stock
|
554,250 |
| 2023-06-30 | Lurier Eliot M |
Interim CFO |
Other↑
|
No Securities Owned
|
0 |
| 2023-06-06 | Wilson John Robert |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option vests on June 6, 2024, subject to the Reporting Person's continued service as a director through the vesting date. |
Stock Option (right to buy)
|
8,000 |
| 2023-06-06 | Knobil Katharine |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option vests on June 6, 2024, subject to the Reporting Person's continued service as a director through the vesting date. |
Stock Option (right to buy)
|
8,000 |
| 2023-06-06 | ELMS STEVE |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option vests on June 6, 2024, subject to the Reporting Person's continued service as a director through the vesting date. |
Stock Option (right to buy)
|
8,000 |
| 2023-06-06 | Eansor Norman David |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This option vests on June 6, 2024, subject to the Reporting Person's continued service as a director through the vesting date. |
Stock Option (right to buy)
|
8,000 |
| 2023-05-10 | Vera Juan |
Director |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
This option vests in equal annual installments on May 10, 2024, May 10, 2025, May 10, 2026 and May 10, 2027 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. |
Employee Stock Option (right to buy)
|
100,000 |
| 2023-02-27 | Koneru Mythili |
Chief Medical Officer |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
This option vests in equal monthly installments over a four year period commencing on March 27, 2023 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. |
Employee Stock Option (right to buy)
|
51,918 |
| 2023-02-27 | Loiacono Michael |
Chief Accounting Officer |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
This option vests in equal monthly installments over a four year period commencing on March 27, 2023 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. |
Employee Stock Option (right to buy)
|
38,480 |
| 2023-02-27 | Szymanska Anna |
Vice President, Quality |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
This option vests in equal monthly installments over a four year period commencing on March 27, 2023 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. |
Employee Stock Option (right to buy)
|
29,947 |
| 2023-02-27 | Hoang Tsvetelina P |
VP, Research and Development |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
This option vests in equal monthly installments over a four year period commencing on March 27, 2023 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. |
Employee Stock Option (right to buy)
|
33,159 |
| 2023-02-27 | Agopyan Nadia |
SVP, Regulatory Affairs |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
This option vests in equal monthly installments over a four year period commencing on March 27, 2023 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. |
Employee Stock Option (right to buy)
|
34,154 |
| 2023-02-27 | Vera Juan |
Director |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
This option vests in equal monthly installments over a four year period commencing on March 27, 2023 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. |
Employee Stock Option (right to buy)
|
46,487 |
| 2022-05-24 | Laskow-Pooley David |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option vests on May 24, 2023, subject to the Reporting Person's continued service as a director through the vesting date. |
Stock Option (Right to Buy)
|
80,000 |
| 2022-05-24 | Knobil Katharine |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option vests on May 24, 2023, subject to the Reporting Person's continued service as a director through the vesting date. |
Stock Option (Right to Buy)
|
80,000 |
| 2022-05-24 | ELMS STEVE |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option vests on May 24, 2023, subject to the Reporting Person's continued service as a director through the vesting date. |
Stock Option (Right to Buy)
|
80,000 |
| 2022-05-24 | Wilson John Robert |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option vests on May 24, 2023, subject to the Reporting Person's continued service as a director through the vesting date. |
Stock Option (Right to Buy)
|
80,000 |
| 2022-05-24 | Eansor Norman David |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option vests on May 24, 2023, subject to the Reporting Person's continued service as a director through the vesting date. |
Stock Option (Right to Buy)
|
80,000 |
| 2022-03-24 | Hoang Peter L. |
Director, President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Represents a restricted stock unit ("RSU") award. |
Common Stock
|
199,094 |
| 2022-03-24 | Kim Anthony H. |
Chief Financial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents a restricted stock unit ("RSU") award. |
Common Stock
|
150,512 |
| 2022-03-24 | Hoang Peter L. |
Director, President and CEO |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld to satisfy tax obligations with respect to the vesting of the RSUs. |
Common Stock
|
48,376 |
| 2022-03-24 | Kim Anthony H. |
Chief Financial Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld to satisfy tax obligations with respect to the vesting of the RSUs. |
Common Stock
|
36,076 |
| 2022-03-24 | Vera Juan |
Director |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares withheld to satisfy tax obligations with respect to the vesting of the RSUs. |
Common Stock
|
33,465 |
| 2022-03-24 | Vera Juan |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents a restricted stock unit ("RSU") award. |
Common Stock
|
140,823 |
| 2022-02-17 | Agopyan Nadia |
SVP, Regulatory Affairs |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
This option vests in equal monthly installments over a four year period commencing on March 17, 2022 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. |
Employee Stock Option (right to buy)
|
40,000 |
| 2022-02-17 | Garrett Gerald |
Vice President, Clinical Ops. |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
This option vests in equal monthly installments over a four year period commencing on March 17, 2022 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. |
Employee Stock Option (right to buy)
|
40,000 |
| 2022-02-17 | Kim Anthony H. |
Chief Financial Officer |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
This option vests in equal monthly installments over a four year period commencing on March 17, 2022 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. |
Employee Stock Option (right to buy)
|
160,000 |
| 2022-02-17 | Vera Juan |
Director |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
This option vests in equal monthly installments over a four year period commencing on March 17, 2022 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. |
Employee Stock Option (right to buy)
|
160,000 |
| 2022-02-17 | Szymanska Anna |
Vice President, Quality |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
This option vests in equal monthly installments over a four year period commencing on March 17, 2022 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. |
Employee Stock Option (right to buy)
|
40,000 |
| 2022-02-17 | Koneru Mythili |
Chief Medical Officer |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
This option vests in equal monthly installments over a four year period commencing on March 17, 2022 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. |
Employee Stock Option (right to buy)
|
160,000 |
| 2022-02-17 | Hoang Peter L. |
Director, President and CEO |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
This option vests in equal monthly installments over a four year period commencing on March 17, 2022 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. |
Employee Stock Option (right to buy)
|
430,000 |
| 2022-02-17 | Loiacono Michael |
Chief Accounting Officer |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
This option vests in equal monthly installments over a four year period commencing on March 17, 2022 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. |
Employee Stock Option (right to buy)
|
140,000 |
| 2022-02-17 | Hoang Tsvetelina P |
VP, Research and Development |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
This option vests in equal monthly installments over a four year period commencing on March 17, 2022 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. |
Employee Stock Option (right to buy)
|
40,000 |
| 2021-12-08 | Knobil Katharine |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
This option vests in equal monthly installments over a three-year period commencing on January 8, 2022, subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. |
Stock Option (Right to Buy)
|
125,000 |
| 2021-06-08 | Wasserman Frederick Gerald |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents the portion of the annual board retainer for each non-employee director payable in immediately vested common stock under the Company's 2020 Equity Incentive Plan and based on the closing price of $3.16 per share, on the day immediately preceding the date of the Company's 2021 annual meeting. |
Common Stock
|
12,658 |
| 2021-06-08 | Eansor Norman David |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents the portion of the annual board retainer for each non-employee director payable in immediately vested common stock under the Company's 2020 Equity Incentive Plan and based on the closing price of $3.16 per share, on the day immediately preceding the date of the Company's 2021 annual meeting. |
Common Stock
|
12,658 |